Most evidence shows that miRNAs inhibit glycolysis in tumor cells by targeting the alternative splicing of PKM, and miR-374b affects the splicing of PKM1/PKM2 by changing the expression of hnRNPA1, which makes sorafenib-resistant hepatocellular carcinoma cells sensitive to sorafenib therapy [38]. This evidence concerns the gene HNRNPA1 and neoplasm.